Vemurafenib, a RAF inhibitor, extends survival in patients with BRAFV600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …

Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E–
mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–mutant cells but …

Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib
due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF …

The activating BRAF mutation V600E and related mutations in this codon are most important
for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) …

The activating BRAF mutation V600E and related mutations in this codon are most important
for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) …

The BRAF inhibitor vemurafenib is currently used for treating patients with BRAF V600E
mutant melanoma. However, the responses to vemurafenib are generally partial and of …

Purpose: NRAS mutations in malignant melanoma are associated with aggressive disease
requiring rapid antitumor intervention, but there is no approved targeted therapy for this …

The RAF inhibitor vemurafenib achieves remarkable clinical responses in mutant BRAF
melanoma patients. However, vemurafenib is burdened by acquired drug resistance and by …

The discovery and development of small molecule inhibitors of mutant BRAF kinase and
MEK kinase have revolutionized the care of patients with melanoma. When used as single …

In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-
sensitive, RAF-inhibitor-resistant adaptive reactivation of ERK signaling. In clinical trials …